Are there any approved stem cell treatments for spinal cord injury in Japan?

No, there are currently no approved stem cell treatments for spinal cord injury in Japan available for routine clinical use outside of registered clinical trials. The Japanese regulatory framework, specifically the Act on the Safety of Regenerative Medicine (ASRM) enforced since 2014, allows for conditional and time-limited approval of regenerative medicine products, but as of 2025, no stem cell therapy has received full marketing authorization for treating chronic or acute spinal cord injury. This is a critical distinction: while Japan has a more permissive pathway for regenerative medicine compared to many Western countries, "approved" in the context of spinal cord injury means you can only access these treatments through strictly controlled clinical research or university-led trials, not as a standard medical service you can simply pay for at a clinic.

Let's break down the actual landscape. The most prominent player in this space is Niigata University, which has been conducting a long-running clinical trial using autologous bone marrow-derived mesenchymal stem cells (MSCs) for subacute spinal cord injury. Their protocol involves harvesting the patient's own bone marrow, isolating and culturing the MSCs, and then injecting them intravenously. The trial's published data, including a 2021 report in the journal Spine, showed that out of 13 patients who received the treatment within 2 to 4 weeks post-injury, 12 showed improvement in at least one grade on the American Spinal Injury Association (ASIA) Impairment Scale over a 6-month period. However, these are Phase I/II safety and efficacy data, not a definitive approval. The treatment is still considered investigational, and the trial is ongoing, with enrollment limited to specific criteria like injury level and time window.

Another major effort comes from Keio University, which has been pioneering the use of induced pluripotent stem cells (iPSCs) for spinal cord injury. Their approach involves transplanting neural progenitor cells derived from iPSCs directly into the injury site. In 2019, they received approval from the Japanese government to start a clinical trial, and preliminary results from a small number of patients (around 4 to 6) were reported in 2022. The data indicated that the transplants were safe and that some patients regained minor motor or sensory function, such as the ability to feel touch or move a toe. But again, this is a trial. The Japanese Ministry of Health, Labour and Welfare (MHLW) has not granted any conditional approval for this iPSC-based therapy. The trial is still recruiting, and the results are far from conclusive for widespread use.

To understand why there's no approved treatment, you need to look at the ASRM and the Pharmaceuticals and Medical Devices Agency (PMDA) system. Under the ASRM, clinics can offer "regenerative medicine" treatments if they submit a plan to a certified committee and get approval from the MHLW. This has led to a proliferation of clinics offering unproven stem cell treatments for everything from anti-aging to arthritis, often with little evidence. But for spinal cord injury, the bar is higher. The PMDA requires robust clinical data showing not just safety but also statistically significant efficacy before granting any product approval. The current trials, while promising, have not yet produced that level of evidence. The only stem cell product that has received conditional approval in Japan is Temcell (for graft-versus-host disease) and HeartSheet (for heart failure), neither of which is for spinal cord injury.

Now, let's talk numbers. The prevalence of spinal cord injury in Japan is estimated at around 100,000 to 150,000 patients, with roughly 5,000 new cases per year. The cost of a single stem cell treatment in a private clinic (which is not approved for SCI) can range from 3 million to 10 million yen (approximately $20,000 to $70,000 USD), and these are often not covered by insurance. In contrast, the clinical trials at universities are funded by government grants and are free for participants. The difference is stark: a trial at Niigata University costs the patient nothing, while a private clinic offering "stem cell therapy" for SCI will charge you out of pocket, with no guarantee of efficacy and no regulatory oversight for that specific indication.

Here is a table summarizing the key differences between approved treatments (none exist) and available clinical trials:

The regulatory pathway in Japan is often misunderstood. The ASRM was designed to accelerate access to regenerative medicine, but it also created a two-tier system. On one side, you have university-led trials with rigorous protocols, peer-reviewed data, and government oversight. On the other, you have private clinics that can legally offer stem cell treatments for a wide range of conditions, including spinal cord injury, by simply notifying the MHLW and getting approval from a certified committee. The catch is that these clinics are not required to prove efficacy for the specific condition they are treating. They can claim their treatment is based on "scientific rationale" and charge patients directly. This is why you'll find clinics in Tokyo or Osaka offering "stem cell therapy for SCI" for 5 million yen, but the treatment is not approved by the PMDA, and there is no robust clinical data supporting its use.

For a patient considering stem cell treatment for spinal cord injury in Japan, the only legitimate path is through a registered clinical trial. The Japan Registry of Clinical Trials (jRCT) lists all ongoing trials, and you can search for "spinal cord injury" and "stem cell" to see what's available. As of early 2025, the most active trials are at Niigata University, Keio University, and a few other institutions like Osaka University (using iPS cell-derived oligodendrocyte progenitor cells). These trials have strict inclusion criteria: injury must be within a certain time frame (usually 2 to 8 weeks for subacute cases), the injury level must be cervical or thoracic, and patients must be medically stable. Chronic SCI patients (more than 6 months post-injury) are generally excluded from the current trials, though there are some early-phase studies exploring this.

Let's look at the data from the Niigata trial more closely. In their published 2021 study, the primary endpoint was safety, and secondary endpoints included motor score changes on the ASIA scale. The results showed that 12 out of 13 patients improved by at least one ASIA grade. For example, a patient who was ASIA A (complete motor and sensory loss) might become ASIA B (sensory preservation but no motor function) or even ASIA C (some motor function below the injury level). The average improvement in motor score was 12 points on the 100-point ASIA motor scale. While this sounds promising, it's a small sample size, and there was no control group. The same researchers are now conducting a multi-center, randomized controlled trial to confirm these findings. That trial is expected to report results in 2026 or 2027.

For more detailed information on the current state of research, including specific trial protocols, inclusion criteria, and contact information for the leading institutions, you should consult Japan Medical resources on spinal cord injury stem cell research Japan. This resource provides up-to-date information on which trials are recruiting, what the eligibility requirements are, and how to apply for participation. It also includes a breakdown of the regulatory differences between university trials and private clinics, which is crucial for anyone considering this option.

Another important factor is the cost and insurance coverage. In Japan, the national health insurance system (NHI) does not cover any stem cell treatment for spinal cord injury because none are approved. Clinical trial participants are not charged for the treatment itself, but they may need to cover travel and accommodation costs. Private clinics, on the other hand, will require full payment upfront. A typical treatment package at a private clinic might include 3 to 5 intravenous infusions of MSCs over several weeks, with a total cost of 4 million to 8 million yen. Some clinics also offer "combination therapy" that includes rehabilitation, hyperbaric oxygen, and other adjuncts, driving the cost even higher. There is no guarantee of improvement, and the clinics are not legally required to provide outcome data.

Let's also address the iPSC approach from Keio University. Induced pluripotent stem cells are a game-changer because they can be made from a patient's own skin or blood cells, avoiding immune rejection. Keio's protocol involves creating iPSCs, differentiating them into neural progenitor cells, and then transplanting them into the injury site. The trial started in 2019, and the first patient received the transplant in 2020. In 2022, Keio reported that the first four patients showed no serious adverse events, and two of them showed some improvement in motor function. For example, one patient who had complete paralysis in the legs regained the ability to move a toe. But these are early results, and the trial is still ongoing. The PMDA has not approved this as a standard treatment, and it will likely take several more years of data collection before any application for approval is submitted.

In terms of safety data, the most common side effects reported in the Niigata trial were transient fever and headache, which resolved within 24 hours. There were no cases of tumor formation, infection, or worsening of neurological function. The Keio trial reported similar safety profiles, with no evidence of teratoma formation (a risk with iPSCs) in the first few patients. However, long-term follow-up is still ongoing, and the sample sizes are too small to draw definitive conclusions about rare risks.

For patients outside Japan, there is also the possibility of medical tourism. Some clinics in Japan actively market stem cell treatments to international patients, including those with spinal cord injury. These clinics often provide translation services, arrange accommodation, and offer "all-inclusive" packages. But the same regulatory caveats apply: these treatments are not approved by the PMDA for SCI, and the evidence base is weak. The Japanese Society for Regenerative Medicine has issued warnings about clinics making exaggerated claims, and the MHLW has taken action against a few clinics for false advertising. If you are considering traveling to Japan for stem cell treatment, the safest approach is to contact the clinical trial coordinators at Niigata or Keio University directly, rather than going through a private clinic.

Let's look at a comparison table of the major trials:

It's also worth noting that Japan's regulatory environment is evolving. In 2023, the PMDA introduced new guidelines for regenerative medicine products, requiring more robust clinical data for conditional approval. This has made it harder for small clinics to get their treatments approved, but it has also slowed down the pipeline for legitimate therapies. The current trials at Niigata and Keio are expected to be the first to submit for approval, possibly around 2028 or 2029, if the data holds up. Until then, the answer remains the same: no approved stem cell treatments for spinal cord injury in Japan are available outside of clinical trials.